Recognition of non-self molecular patterns by pattern recognition receptors is a cornerstone of innate immunity. Toll-like receptors (TLRs) exert a key role in recognizing pathogen-associated molecular patterns (PAMPs) but have also been implicated in the recognition of damage-associated molecular patterns (DAMPs). As such, TLRs regulate a wide range of biological responses including inflammatory and immune responses during carcinogenesis. The high expression of TLRs by antigen-presenting cells, including dendritic cells, and their ability to induce antitumor mediators such as type I interferon has led to efforts to utilize TLR agonists in tumor therapy in order to convert the often tolerant immune response toward antitumor responses. However, TLRs are also increasingly recognized as regulators of tumor-promoting inflammation and promoters of tumor survival signals. Here, we will review in detail the dichotomous role of TLRs in tumor biology, focusing on relevant TLR-dependent pro-and antitumor pathways, and discuss clinical applications of TLR-targeted therapies for tumor prevention and treatment.
INTRODUCTION
One hundred fifty years after Virchow's postulate, the link between inflammation and cancer has been firmly established by epidemiologic investigations and animal studies. 1, 2 In all, 18% of human cancers are attributable to infection, and chronic inflammation triggered by infection is an important contributor to carcinogenesis. 3, 4 In addition, injury may trigger local inflammation 5 and obesity can contribute to a general hyperinflammatory state. 6 Although many tumors arise in the setting of inflammation, it is present in virtually all established tumors. Although inflammation is controlled by numerous mediators and pathways, several systems function as key upstream regulators. Among these are pattern recognition receptors (PRRs) that sense danger by detecting non-self or altered molecular patterns. Toll-like receptors (TLRs) are the bestcharacterized PRRs for the detection of pathogen-associated molecular patterns (PAMPs). PAMP-induced TLR activation triggers a profound activation of multiple proinflammatory and anti-viral signaling cascades to achieve pathogen elimination. However, if pathogens cannot be eliminated, they may elicit chronic inflammation, which may also in part be mediated through TLRs. 7, 8 The important contribution of inflammation to carcinogenesis is best exemplified by high rates of colorectal cancer in inflammatory bowel disease, high rates of gastric cancer in patients infected by Helicobacter pylori, and high rates of hepatocellular carcinoma in patients with chronic hepatitis. 1 Accordingly, TLR-induced inflammation may act as a promoter of carcinogenesis, with recent studies showing strong promotion of carcinogenesis in the colon, liver, stomach and pancreas by TLRs. [9] [10] [11] [12] [13] In addition to PAMP-induced TLR activation, inflammation and injury also induce the release of endogenous molecules termed damage-associated molecular patterns (DAMPs), some of which act as ligands for TLRs. 5 Notably, signals triggered by DAMPs may promote carcinogenesis in a TLR-dependent manner.
14 On the other hand, inflammatory responses may not only provide tumor-promoting signals but also contribute to antitumor immune responses. 15, 16 After decades of debate, cancer immunosurveillance has been convincingly proven, as demonstrated by increased tumor rates in RAG2 À / À mice or mice that lack interferon-g (IFNg) signaling. 17 However, we still do not know how well and in what type of tumors this system works. Based on increased immunogenicity of tumor transplants from immunosuppressed mice, it has been suggested that this system contributes to tumor elimination in early stages, but that escape mechanisms develop, resulting in long-term failure. 16 One interesting aspect linking bacterial PAMPs and antitumor responses are historic observations, made by Busch, Bruns and Coley, that bacterial infections such as erysipelas or injection of heat-killed Streptococcus pyogenes and Serratia marcescens ('Coley's toxin') may lead to tumor regression and sometimes even cure. [18] [19] [20] [21] Although the mechanisms behind these historic studies remain obscure, recent advances in TLR biology and clinical studies with TLR agonists have suggested that TLR activation may indeed represent a relevant antitumor pathway, allowing to convert immune tolerance to antitumor immune responses. [22] [23] [24] [25] Here, we will briefly review TLR signaling, before discussing the dichotomous role of TLRs in tumor biology, with a particular focus on mechanisms by which TLRs may promote or inhibit cancer. Finally, we will highlight potential applications of TLR-targeting drugs for tumor prevention and therapy.
TLRS AND TLR SIGNALING
TLR signaling has been reviewed in detail elsewhere, [26] [27] [28] and we will only summarize key concepts. TLRs are PRRs that recognize a wide range of bacterial, viral and fungal PAMPs, as well as endogenous DAMPs such as high-mobility group box 1 (HMGB1). Although individual TLRs recognize distinct ligands, the mechanisms of TLR activation and signal transduction are highly conserved (see Figure 1 ). Ligand binding occurs via leucine-rich repeats of extracellular TLR domains and triggers signal transduction pathways through interaction of intracellular Toll/interleukin-1 receptor domains with conserved adaptor molecules. Most TLRs signal through the adapter molecule myeloid-differentiation factor 88 (MyD88). Only TLR3 and TLR4 signal through a MyD88-independent pathway that relies on the adapter molecule Trif. TLR4 is the only receptor that signals through MyD88 and Trif. The MyD88-dependent and MyD88-independent pathways activate multiple proinflammatory signaling cascades including nuclear factor (NF)-kB, c-Jun N-terminal kinase/AP1, extracellular signalregulated kinase and p38, and as well as the IFN pathway. [26] [27] [28] TUMOR-PROMOTING ACTIONS OF TLRS TLRs may promote carcinogenesis through proinflammatory, anti-apopototic, proliferative and profibrogenic signals in either the tumor microenvironment or tumor cells themselves, as described below. These effects can be either induced directly in TLR-expressing target cells, or mediated by TLR-induced cytokines.
TLR-mediated inflammation
TLRs are key regulators of inflammatory signaling, mediated by MyD88-dependent and MyD88-independent pathways. One important tumor-promoting signaling pathway induced by TLR signaling is the transcription factor NF-kB. NF-kB is a master switch of inflammation regulating the transcription of 4100 proinflammatory genes, 29 and is closely related to the avian viral oncoprotein v-Rel. 30 TLR signaling upregulates well-known tumorpromoting inflammatory cytokines through NF-kB-dependent pathways, including interleukin (IL)-1b, tumor necrosis factor a (TNFa) and IL-6. [31] [32] [33] These cytokines promote cancers in the intestine, liver, stomach and skin. [34] [35] [36] [37] [38] [39] [40] TLR2-mediated inflammatory signals in macrophages, triggered by tumor-derived, TLR2-agonistic extracellular matrix (ECM) protein versican, promote the secretion of TNFa and metastasis. 41 Besides inflammation, NF-kB activation results in a wide range of cellular responses such as prevention of apoptosis (discussed below), proliferation and antioxidant defenses. 42, 43 Oxidative stress that typically occurs in the setting of chronic inflammation may not only contribute to the activation of tumor-promoting inflammatory signaling pathways 44 but also change molecular patterns and result in formation of DAMPs with TLR2-activating properties by lipid oxidation. 45 TLR-mediated anti-apoptotic effects Resisting cell death is a hallmark of cancer, 46 ,47 counteracting many of the control mechanisms that destroy malignant cells. NF-kB is considered the most relevant anti-apoptotic pathway that controls the expression of anti-apoptotic genes and also restricts the activation of proapoptotic pathways such as c-Jun N-terminal kinase. 48, 49 TLR signaling activates NF-kB both through MyD88-dependent and MyD88-independent pathways. Moreover, TLRs stimulate the release of cytokines IL-1b and TNFa that in turn promote NF-kB activation in target cells. The key role of TLR signaling in cytoprotection is highlighted by the enhanced susceptibility of MyD88-deficient mice to dextrane sulfate sodium (DSS)-induced colitis, 50 which is at least in part mediated by decreased in cytoprotective pathways. Similarly, in the liver and the lung, toxic injury is suppressed in a TLR-dependent manner.
9,51,52 TLR signaling may not only have a role in regulating injury responses in chronically injured precancerous organs but also in promoting survival of malignant cells. As such, TLR-induced NF-kB activation promotes tumor cell survival in colon cancer, 53 liver cancer, 9 stomach cancer 11 and lung cancer. 54 Moreover, TLR4 on tumor cells mediates resistance Figure 1 . TLR signaling. TLRs bind bacterial and viral PAMPs, leading to the activation of proinflammatory and anti-viral signaling pathways including NF-kB and interferon regulatory factor-3 (IRF3) and 7 (IRF7), respectively. Activation of these pathways is mediated by two key adaptor molecules MyD88 and Trif. Key biological effects of NF-kB activation include prevention of apoptosis and increased inflammation. Type I IFN induces anti-viral and antitumor immunity.
of tumor cells to cell death induced by cytotoxic T lymphocytes and promotes tumor growth in vivo. 55 In addition to NF-kB activation in TLR-expressing tumors, survival signals could also be provided by TLR-expressing cells in the tumor microenvironment such as tumor-associated macrophages or cancer-associated fibroblasts that release IL-1b or TNFa, which then act on tumor cells (see Figure 2 ). Conditional ablation of TLRs in tumor cells and the tumor microenvironment will be required to differentiate between these two possibilities.
TLR-mediated promotion of wound healing The similarities between tumor stroma and wounds have led to the suggestion that cancers represent 'wounds that do not heal' and a final stage of uncontrolled tissue repair processes. 56 Woundhealing responses may strongly promote carcinogenesis as demonstrated by studies with Rous sarcoma virus, in which injury and wound healing of infected animals amplifies carcinogenesis. 57 The two events in the wound-healing response that are influenced by TLR signaling include (i) epithelial regeneration and (ii) myofibroblast activation. The liver is the best-known example for the epithelial regeneration with restoration of mass after 70% partial hepatectomy within 7-10 days. Although deletion of single TLRs does not affect regeneration, deletion of the common TLR adapter MyD88 or elimination of intestinally-derived TLR ligands in germ-free mice suppresses liver regeneration. [58] [59] [60] A contribution of TLR signaling to regeneration is also found in the intestine, where a TLR2/TLR4/MyD88 signaling cascade mediates epithelial regeneration after DSS-mediated injury, 53, 61 and in the skin, where lack of MyD88 slows the healing of excisional skin wounds. 62 In the intestine and liver, TLR-MyD88 signaling regulates the expression of mitogenic epidermal growth factor receptor ligands epiregulin and amphiregulin in non-hematopoietic cells. Accordingly, epiregulindeficient mice display decreased tumor development in the liver and colon. 9, 63 The accumulation of ECM constitutes a second event that may promote carcinogenesis in a TLR-dependent manner. Fibroblasts and fibroblast precursors functionally express TLR2, 64, 65 TLR4, [66] [67] [68] [69] and TLR9. 70 Notably, TLR4 promotes fibrosis development in the liver, as demonstrated by the protective effect of TLR4-, CD14-, MD-2-, MyD88-and Trif deficiency. [71] [72] [73] Mice lacking TLR2 and TLR9 also display a reduction of hepatic fibrosis. 70, 74 TLRs exert only moderate profibrogenic effects in other organs, such as skin and kidney, but have no role in lung fibrosis. 75 
TLR-MEDIATED ANTITUMOR SIGNALS
Although the concept of tumor immunosurveillance is well established, the immune system is much more efficient at triggering dendritic cell (DC) activation in response to pathogens than at recognizing and eliminating tumors. In the past two decades, pharmacologic studies have established that boostering the activation of pathways, which is efficiently triggered by pathogens but not by tumors, such as TLRs and downstream mediators such as type I IFNs, can be therapeutically used to shift the balance from immunotolerance to antitumor effects. In particular, TLR7 agonists and IFN alpha have shown therapeutic efficacy in melanoma, basal cell cancer, renal cell cancer and hairy cell leukemia. On the other hand, chronic low-grade stimulation of TLRs, in particular TLR2 and TLR4, leads to tumor-promoting inflammation and prevention of tumor apoptosis. This may be mediated through effects on tumor-associated macrophages (TAMs), cancer-associated fibroblasts or through direct effects in the tumor. NF-kB activation has a key role as it not only fuels inflammation but also prevents apoptosis. Finally, tumor-secreted factors, such as versican, may activate TLRs on cells of the tumor microenvironment, further fueling tumor-promoting inflammatory signals.
DC. 77 As professional APCs, which express a large number of PRR including TLRs and exert powerful effects on lympho cytes, DCs are at the interface of innate and adaptive immune responses. Although DC have been in the focus of tumor immunology for their ability to launch potent antitumor responses, lacking activation of DC, often resulting from inhibitory signals from tumor cells, may also induce immune tolerance through T-cell deletion or through regulatory T cells (Treg), 77 ,78 thus allowing tumor progression. As type I IFN is absolutely required for immune rejection of tumors by DC, 79, 80 activation of the TLR-IFN signaling pathway represents a therapeutic approach to shift the balance from DC tolerance to antitumor response. TLR-activated DC may mediate antitumor responses not only through antigen presentation and effects on T cells 81, 82 but also through direct cytotoxic effects on tumor cells. Accordingly, both classical and plasmacytoid DC, activated by TLR7 agonists, acquire the ability to induce antitumor responses and lyse tumor cells. [83] [84] [85] Similarly, TLR5 activation also increases tumoricidal activity of DC. 86 It is possible that DC-mediated tumor killing subsequently triggers a more efficient antigen presentation to cytotoxic T lymphocytes, thus amplifying antitumor responses. Different DC subsets such as TLR9-stimulated plasmacytoid DC and myeloid DC engage in a crosstalk that promotes antitumor responses. 87 TLR-and IFN-mediated effects on natural killer cells One of the earliest described immunoregulatory functions of type I IFN-its ability to regulate natural killer (NK) cell functions, 88 has now been proven to be one of the major mechanisms of the regulation of tumor growth by endogenous type I IFN. Poly I:C-mediated TLR3 stimulation of myeloid DC induces NK activation and NK-mediated tumor regression in a mouse model of melanoma. 89 A novel molecule termed interferon regulatory factor-3-dependent NK-activating molecule provides a link between myeloid DC and NK cells. 89 Inhibition of regulatory T-cell functions by TLR signals CD4 þ CD25 þ Tregs have an important role in immunity and tolerance as evidenced by development of organ-specific autoimmune diseases following their depletion. 90 Activation of TLRs on DC regulates T-cell activation not only through major histocompatibility complex class II and costimulatory molecules, but also through TLR-induced signals in DC that block the suppressive effect of Tregs in an IL-6-dependent manner. 91 In addition, synthetic and natural ligands for human TLR8 can directly inhibit Treg cell function, independent of DC, and promote antitumor immunity. 92 Altogether, these data demonstrate that TLR activation can release the brake in antitumor immunity via Tregs.
Additional mechanisms through which TLRs exert antitumor effects Treatment with TLR3 agonist poly I:C may induce tumor regression by converting tumor-supporting macrophages to tumor suppressors that produce inflammatory cytokines and promote M1 polarization. This response is mediated by TNFa through a MyD88-independent pathway. 93 TLR9 agonists can also exert antitumor effects through suppression of angiogenesis. 94 It is likely that TLR-induced IFNs have an important role as IFN alpha is well known to reduce tumor growth by blocking angiogenesis. [95] [96] [97] 
ROLE OF SPECIFIC TLRS AND THEIR LIGANDS IN EXPERIMENTAL AND HUMAN CARCINOGENESIS
The most profound contribution of TLRs to carcinogenesis has been observed in organs that are either directly exposed to bacterial TLR ligands such as the GI tract and skin, or indirectly exposed to high amounts of intestinal TLR ligands such as the liver. Thus, tumor-promoting proinflammatory TLR activation seems to be triggered by bacterial PAMPs. Accordingly, germfree animals display reduced carcinogenesis in the liver and the GI tract.
9,98-100 However, in other organs, for example, the pancreas, DAMPs may be the main stimulus for TLR-dependent carcinogenesis.
TLRs exert a dichotomous role in cancer. The amplitude and length of receptor activation may have a critical impact on outcome, with chronic low-grade TLR activation favoring a tumorpromoting proinflammatory state, and high-dose therapeutic TLR activation promoting antitumor response. Here we summarize results from the most relevant studies and classify TLRs as 'largely tumor-promoting' or 'largely tumor-suppressing', with the caveat that TLRs have divergent functions in an organ-, cell-, context-and ligand-dependent manner, and that the literature contains conflicting data.
TLRs and TLR adapter molecules with largely tumor-promoting functions TLR4. Tumor-promoting functions of TLR4 are best established in the colon, liver, pancreas and skin. In colon, where there is constant interaction between gut microbiota and epithelial cells, TLR4 deletion strongly reduces inflammation and tumor burden in a colitis-associated neoplasia using the azoxymethane (AOM)-DSS model. 101 Furthermore, transgenic mice overexpressing constitutively activated TLR4 in the intestine exhibit a higher sensitivity to colitis-associated neoplasia. 102 These studies are in agreement with other studies in which either deletion of the TLR4 adapter molecule Myd88, 103 or depletion of the gut microbiota, which supplies TLR4-activating PAMPs such as lipopolysaccharide (LPS), reduce colon cancer development. 103, 104 In contrast, one recent study showed that intestinal overexpression of constitutively activated TLR4 in the APC Min model of colon reduces tumor load by increasing tumor cell apoptosis. 105 In the liver, several studies have demonstrated a tumor-promoting role of TLR4. 9, 51 Moreover, germ-free status or elimination of the gut microbiota by antibiotics decrease hepatocarcinogenesis. 9 Similarly, dysbiosis induced by penicillin increases development of liver cancer whereas treatment with probiotics improves it.
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TLR4-dependent hepatocarcinogenesis is mediated by non-bone marrow-derived cells. In contrast to these numerous studies, a single study showed increased hepatocarcinogenesis in TLR4-deficient mice. 107 In the skin, TLR4-and Myd88-deficient mice exhibited a strong reduction in tumor numbers induced by twostep chemical carcinogenesis. 39, 108 Carcinogenesis in the skin depends on TLR4 expressed by myeloid and epithelial cells, and the endogenous TLR4 ligand HMGB1. MyD88-dependent promotion of skin carcinogenesis not only depends on TLR but also on IL-1R signaling. 39 The fact that TLR4 exerts a protective role in a non-inflammatory model of skin carcinogenesis suggests that the effect of TLR4 on skin cancer may be context dependent. 109 In the pancreas, TLR4 deletion decreases tumor growth, while chronic LPS treatment accelerates cancer progression. 13 Tumorpromoting effects of TLR4 in pancreatic cancer are mediated by bone marrow-derived cells. 13 In contrast to largely tumorpromoting role of TLR4 in the colon, liver, skin and pancreas, TLR4 in lung and breast inhibits cancer development: mice expressing non-functional TLR4 exhibit increased tumor load in a 3-methylcholanthrene-induced lung cancer model. 110 Similarly, TLR4 promotes breast cancer development, progression and metastasis in chemical carcinogenesis and syngeneic transplant models. 111, 112 Further studies are required to understand the organspecific contribution TLR4. It is conceivable that TLR4-activating PAMPs act predominantly as potential tumor promoters, whereas DAMPs function as potential tumor suppressors. Accordingly, chemotherapeutic drugs or radiotherapy require TLR4-activating DAMPs to achieve therapeutic effects: HMGB1 is released following anthracycline treatment or radiotherapy resulting in HMGB1-mediated TLR4 activation on DC and tumor elimination by tumorspecific T cells. 113 Despite the large body of literature on TLR4 in experimental carcinogenesis, the functional contribution of TLR4 to human carcinogenesis is not well understood. Single-nucleotide polymorphisms that render TLR4 less responsive, such as Asp299Gly and Thr399Ile, may be associated with precancerous gastric lesions, and increased risk of gallbladder cancer. 114, 115 However, large-scale confirmatory studies are missing. The contribution of other TLR4 single-nucleotide polymorphisms to carcinogenesis remains elusive. 116 Patients who received anthracycline-based adjuvant chemotherapy for breast cancer had increased metastasis and decreased metastasis-free survival when carrying the Asp299Gly TLR4 variant, confirming the contribution of TLR4 to chemotherapy and radiotherapy. 113 Toll-like receptor-2. TLR2 may promote or suppress tumor growth in a context-dependent manner. A profound tumor-promoting role has been observed in gastric cancer. TLR2 is upregulated in human and murine gastric cancer samples. 11 In a genetic mouse model of gastric cancer, deletion of TLR2 results in a drastically reduced tumor load.
11 TLR2-mediated promotion of gastric cancer is independent of bone marrow-derived cells, and is mediated by proliferation and survival signaling pathways including phosphatidylinositol 3 kinase/Akt, extracellular signal-regulated kinases 1 and 2 and NF-kB in the epithelial compartment. 11 In lung cancer, TLR2 exerts tumor-and metastasis-promoting effects. Lung cancer cells secrete extracellular matrix component versican, resulting in versican-mediated TLR2 stimulation and IL-6 and TNFa production in macrophage and promotion of metastatic growth. 41 In the liver, TLR2 does not affect hepatocarcinogenesis in the setting of chronic injury. 9 However, in a purely genotoxic model of liver cancer, TLR2 knockout mice exhibit a higher number of tumors and decreased survival. 117 Tumor cells from TLR2 knockout mice showed a lower amount of cell death and a suppressed senescence program. Similar to the liver, the role TLR2 remains controversial in colorectal cancer. In one study, there were no differences in colorectal cancer between wild-type and TLR2-deficient mice using the AOM-DSS model. 118 In contrast, another study reported increased tumor development and higher IL-6, IL-17A and phospho-STAT3 levels in colorectal cancer in TLR2-deficient mice using a similar AOM-DSS model. 119 TLR2 may also be the mediator of angiogenesis-promoting lipid oxidation end products such as o-(2-carboxyethyl)pyrrole. 45 These products are not only generated during inflammation and wound healing but accumulate in highly vascularized tumors such as melanoma, and induce a vascular endothelial growth factor-independent angiogenic response that depends on TLR2. 45 The role of TLR2 in human carcinogenesis is not well understood. In gastric cancer, the STAT3 (signal transducers and activators of transcription 3) pathway activation and increased TLR2 expression are associated with poor survival. 11 Although TLR2 polymorphisms have been associated with gastric and cervical cancer risk, 120 ,121 large-scale confirmatory studies are missing.
Adaptor molecules and regulators of TLR signaling. MyD88 mediates downstream signaling of the majority of TLR family members, as well as the receptors for IL-1 and IL-18 (see Figure 1) . The L265P mutation in the Toll/interleukin-1 receptor domain of MyD88 mutations caused constitutive activation of NF-kB and Janus kinase-STAT pathways and increased survival of malignant cells, thereby contributing to the pathogenesis of diffuse large B-cell lymphoma and Waldenströ m's macroglobulinemia. [122] [123] [124] Conversely, deletion of MyD88 decreases carcinogenesis in many settings, including genetic and chemical models of colon cancer, 103 chemically-induced hepatocarcinogenesis 36 and chemical models of skin papilloma and fibrosarcoma. 125 In contrast, deletion of MyD88 results in aggressive fibroinflammation, increased Th2 responses and profoundly accelerated tumorigenesis in a genetic model of pancreatic cancer. 13 In the latter model, carcinogenesis is driven by the MyD88-independent TRIF pathway, suggesting that MyD88 deletion might promote tumors by overactivation of the TRIF pathway. 13 SIGIRR is a member of the TLR/IL-1 receptor superfamily, and acts as a negative regulator of TLR and IL-1 signaling. 126 Mice deficient in SIGGIR not only display constitutive expression of inflammatory genes in the colon, which depends on the bacterial microbiota, but also increased inflammation following DSS, and increased tumorigenesis in the AOM þ DSS model. 127 TLRs with largely tumor-suppressive functions Toll-like receptor 3. TLR3 predominantly serves a tumor-suppressive function, largely mediated by TLR3-dependent stimulation of antitumor immunity. Accordingly, TLR3 deficiency results in development of acute lymphoblastic T-cell leukemia after infection with endogenous retrovirus. 128 In syngeneic and xenograft models of prostate cancer, TLR3-deficient mice display increased tumor growth rate. 129 Conversely, treatment with TLR3 agonist poly I:C inhibits tumor growth in the latter model and a genetic model of prostate cancer overexpressing the TRAMP transgene. 129 Systemic administration of poly I:C reduces the growth of melanoma metastasis. 130 In the liver, there is a positive correlation between TLR3 expression and patient survival. 131 Moreover, poly I:C treatment increased NK cell activation and reduced liver tumor growth in a syngeneic transplant model. 131 Consistently in all models, TLR3 downstream effects are mediated by type I IFN and subsequent NK cell or DC activation, and NK cell-or DC-mediated death of tumor cells. However, in contrast to the above studies, it has also been suggested that TLR3 could promote tumor development through effects on cell proliferation and survival. 132, 133 Toll-like receptor 5. The majority of studies deciphering the contribution of TLR5 to tumor development have revealed potent antitumor effects, consistent with the expression and function of TLR5 on DC and their important role in antitumor immune responses. These effects are best exemplified in a study where tumor cell lines expressing TLR5 agonist flagellin fused with a tumor antigen induced DC-mediated antitumor immune response. 82 In the colon, knockdown of TLR5 or MyD88 markedly enhanced growth and inhibited necrosis in a xenograft model.
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TLR5 is highly expressed in human breast cancer biopsies compared with non-tumor tissue. 135 Implantation of TLR5-deleted breast tumor cells results in enhanced tumor growth while TLR5 agonist flagellin retarded tumor growth by increasing cell death and decreasing tumor cell proliferation. 135 However, the use of immunodeficient mouse models that lack DC, is an important limitation of the above studies. Therefore, the tumorsuppressive function of TLR5 requires additional investigations in mice with a fully functional immune system.
Toll-like receptor 7/Toll-like receptor 8. TLR7 and TLR8 are structurally related receptors for single-stranded RNA, TLR7 and TLR8 have been the focus of research on TLRs and cancer because of the profound immunomodulatory and antitumor effects of small-molecule agonists. [136] [137] [138] [139] Although there is considerable data on the clinical application of potent TLR7/TLR8 agonists for antitumor therapy, relatively little is known about the contribution of endogenous TLR7/TLR8 activation to carcinogenesis. A recent publication demonstrated that microRNAs, released from tumors via exosomes, bind to TLR7 and TLR8, and favor metastatic growth, 140 suggesting that low-level activation of TLR7/TLR8 by endogenous agonists exert tumor-promoting effects. TLR7/TLR8 agonists are predominantly used for antitumor therapy of basal cell carcinoma and melanoma 136 (discussed in the next section). Antitumor effects are predominantly mediated by TLR7/TLR8 activation on DC, resulting in their recruitment, activation and ability to kill tumor cells. 83, 85 Moreover, TLR7/TLR8-activated DC also activate NK cells and suppress Treg. 92, 141, 142 Despite the overwhelming literature on antitumor effects of TLR7/TLR8 agonists recent studies suggest a potential tumor-promoting role TLR7/TLR8 in some settings: in pancreatic cancer, there is not only a high expression of TLR7 in both epithelial and inflammatory cells, but also an acceleration of tumor formation following TLR7 activation. 12 Conversely, pharmacologic inhibition of TLR7 decreases pancreatic cancer. TLR7 exerts its effects on pancreatic cancer in inflammatory cells as chimeric mice with absent TLR7 expression in bone marrow-derived cells displayed decreased carcinogenesis. 12 In the lung, both TLR7 and TLR8 are expressed on tumor cells, and promote the survival of lung cancer cell lines through NF-kB activation and upregulation of Bcl-2. 54 As discussed above, TLR7/TLR8-agonistic microRNAs promote lung tumor growth. 140 Thus, the effects of TLR7/TLR8 on tumor may depend on the organ, tumor stage, the cell type, and the role that antitumor immune responses have in a particular tumor. In light of the potential clinical applications of TLR7/TLR8 agonists for antitumor therapies, further pharmacologic and genetic studies are required to understand in which organs and settings TLR7/ TLR8 signaling promotes cancer.
Toll-like receptor 9. TLR9 is the receptor for non-methylated CpG DNA that is typically found in viral and bacterial DNA. 143 Similar to TLR7/TLR8, TLR9 has been extensively studied for its role in immunosurveillance and as potential target for antitumor therapy using synthetic TLR9 agonists. The contribution of TLR9 to immunosurveillance is highlighted by the fact that TLR9 deficiency results in acute lymphoblastic T-cell leukemia after infection with endogenous retrovirus. 128 These data suggest that TLR9 may be particularly relevant for virally-induced tumors. Conversely, TLR9 activation by synthetic oligodeoxynucleotide agonists (CpG-ODN) has demonstrated antitumor activity in xenograft models of murine cervical carcinoma, neuroblastoma and colon cancer. [143] [144] [145] [146] [147] Similarly, the combination of TLR9 agonists with Stat3 small interfering RNA in a single molecule promoted antitumor responses against subcutaneously implanted melanoma cells, while at the same time suppressing the Stat3-mediated immunosuppression in the tumor microenvironment. 148 CpG-ODNs are studied for the treatment of different tumor types as a single therapeutic agent, 143 as well as in combination with radiation therapy and cytotoxic chemotherapy 149 (discussed in the next section). Mechanistically, TLR9 agonists induce type I IFN secretion in DC resulting in cytotoxic DC, activation of NK cells and cytotoxic T lymphocytes, all of which contribute an antitumor immune response. 143, [150] [151] [152] [153] In addition to immune cells, TLR9 is also expressed on tumor cells from many tissues 55, 154 but the function of TLR9 on tumor cells in vivo is currently not known. As it is conceivable that TLR9 stimulation may be cell-and context dependent and possibly contribute to tumor cell survival or proliferation, additional studies in TLR9-deficient mice are needed to investigate the functional role of TLR9 in carcinogenesis in vivo.
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TLRS AS THERAPEUTIC TARGETS FOR TUMOR PREVENTION AND THERAPY
Once ranked among the top 20 immunotherapy drugs for the cure of cancer, the role of TLRs in cancer biology has not only become more complex with recent studies revealing a tumor-promoting effect of several TLRs, but has also been set back by disappointing results from several phase II and phase III clinical trials. 159 Altogether, these results are leading to more differentiated approaches that requires focus on (i) tumors amenable to immunotherapy, (ii) TLRs that promote antitumor responses most efficiently and for which a tumor-promoting role has been excluded and (iii) combination therapies to boost immune responses to specific antigens, targeting in particular DC. The majority of clinical trials have been performed using TLR3, TLR7/ TLR8 and TLR9 agonists (Figure 3a) . On the other side of the spectrum of TLR biology, targeting specific tumor-promoting TLRs such as TLR2 and TLR4, or their ligands for tumor prevention represents a new and evolving philosophy that could eventually be translated into clinical trials for primary or secondary tumor prevention.
TLR agonists for the induction of antitumor responses TLR7/TLR8 agonists. The most successful translation of immunomodulatory and anticancer effects of all TLR agonists has been achieved for TLR7/TLR8. Accordingly, the TLR7/TLR8 agonist imiquimod is the only TLR agonist approved for cancer therapy. As TLR7 and TLR8 both recognize single-stranded RNA, many synthetic agonists activate both receptors. Several classes of TLR7/ TLR8 agonists have been developed: 160 Imidazoquinoline, which resemble adenosine analogs, include the TLR7 agonist imiquimod 138 and the TLR7/TLR8 agonist resiquimod; guanosine analogs such as the TLR7 ligand loxoribine; and single-stranded RNA that has been stabilized to prevent its rapid degradation. Modifications of their RNA sequence can direct ligands specifically toward TLR7 or TLR8. 142 Among all TLR7/TLR8 ligands, imiquimod is the best studied 136 and in clinical use: topical administration of Aldara (5% imiquimod cream) has been approved by the Food and Drug Administration (FDA) and the European Union for the treatment of basal cell carcinoma, and achieves a clearance rate of 42-100%. 161, 162 Imiquimod is also being used to locally treat other cutaneous tumors including melanoma with well-documented clearance rates and 485% success rates for lentigo maligna 163 ( Figure 3b) . Evidence is accumulating that it may also be effective in more advanced stages such as invasive cutaneous and locally recurrent melanoma. [164] [165] [166] Topical imiquimod treatment is also utilized in a phase II clinical trial in breast cancer patients with chest wall recurrence or cutaneous metastasis 22, 167 (Figure 3b ). Despite success with topical treatment, the role of TLR7/TLR8 agonists for systemic therapy remains uncertain. Unlike imiquimod, the TLR7 agonist 852A and the TLR8 agonist VTX-2337 can be applied systemically and are currently being evaluated in phase I and phase II clinical trials for various cancers including melanoma breast, ovarian, endometrial, cervical and head and neck cancers (Figure 3b ).
Toll-like receptor 9. Although a large number of clinical trials have been performed using TLR9 agonists, there is currently no FDA-approved TLR9 agonist for tumor therapy. A number of CpG-containing TLR9 agonists have been tested in animal models, including cervical carcinoma, neuroblastoma and colon cancer, [143] [144] [145] [146] [147] and in clinical trials. 22 Despite promising preclinical studies, several clinical trials have been disappointing: for example, failure of TLR9 agonists CGP 7909 in a phase III trial in non-small cell lung cancer, and safety concerns of IMO-2055 in combination with platinum-based therapies phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck cancer, respectively. 159 Results from other ongoing studies of TLR9 agonist MGN1703 for metastatic colorectal cancer and TLR9 agonist EMD1201081 for head and neck cancer (Figure 3b ) need to be awaited to judge the role of TLR9 in cancer therapy. As a result of these somewhat discouraging clinical studies, focus has shifted toward the ability of TLR9 agonists to activate DC and improve responses to tumor vaccines. The combination of the TLR9 agonist CPG7909, the TLR4 agonist monophosphoryl lipid A and the melanoma antigen MAGE-A3 is currently being tested in a phase III clinical trial (Figure 3b ).
Toll-like receptor 5. Although there is significant data in mice showing antitumor effects by TLR5 agonists flagellin 82, 135, 168 and TLR5-agonistic polyethylenimine-based nanoparticles, which are selectively engulfed by tumor-associated tolerogenic DC, 86 translation into clinical practice has not been achieved. CBLB502 (Entolimod) is a TLR5 agonist that is derived from Salmonella flagellin 169 that is currently studied in phase I clinical trials in patients with squamous cell head and neck cancer, and in locally advanced or metastatic solid tumors (Figure 3b ).
Toll-like receptor 3. Despite evidence of tumor-suppressing effects of TLR3 ligand poly I:C in several mouse studies, 129, 130 there is little data on antitumor effects of TLR3 ligands in humans. As poly I:C is inactivated rapidly in humans, several TLR3 ligands have been developed for clinical applications. Poly-ICLC (Hiltinol) is a derivative of poly I:C that has been stabilized with poly-lysine, and is currently studied in phase II trials for solid tumors (Figure 3b ). Rintatolimod (Ampligen) is a derivate of poly I:C in which cytidine is replaced by uridine at a ratio of 1:12 (polyI:polyC 12 U). Rintatolimod is used in combination with vaccines for the treatment of ovarian and fallopian tube cancer, as well as brain tumors (Figure 3b) . The double-stranded RNA mimic IPH-3102 is another TLR3 agonist, but there is no available data on animal studies or clinical trials.
TLR2, TLR4 and mixed agonists. Although TLR2 and TLR4 mediate tumor promotion in many types of mouse cancers, they may exert antitumor effects in others, and have been investigated for tumor therapy as well as adjuvants for vaccination. Although strictly not a pure TLR agonist, Bacillus Calmette-Gué rin (BCG) mediates many of its immunomodulatory effects through TLR2 and TLR4. 24 Antitumor effects of BCG are known for over 40 years. [170] [171] [172] [173] BCG is effective in the treatment of bladder cancer [174] [175] [176] ( Figure 3b ) and has been approved by the FDA for this purpose. BCG remains the only known effective tumor therapeutic with TLR2/TLR4 agonistic effects. Although BCG has been evaluated in clinical trials for a large number of other tumors, these have been largely disappointing. 25 OM-174 (CXR-526), a derivative from Escherichia coli lipid A, is a mixed TLR2/TLR4 agonist. OM-174 has been evaluated in a phase I study in patients with solid tumors, and is an adjuvant for an autologous DC vaccine for melanoma in a phase I/II clinical trial (Figure 3b ). Stimuvax is a cancer vaccine against the tumor antigen MUC1 that contains TLR4 agonist monophosphoryl lipid A, but failed to improve non-small cell lung cancer. 177 In summary, with the exception of the nonspecific TLR2/TLR4-agonistic BCG, there is currently no data showing clear antitumor activity of TLR2 or TLR4 agonists in clinical trials.
TLR antagonism for tumor prevention. Based on recent data on tumor-promoting effects of TLRs in organs such as the colon, liver and pancreas, inhibition of TLR signaling may represent a novel strategy for tumor prevention. However, knowledge from animal models has not been translated into the clinic and there are currently no ongoing trials. Here we summarize potential therapeutic strategies for tumor prevention:
Modulation of gut microbiome and bacterial translocation by probiotics and antibiotics. The gut microbiome is the main source for bacterial TLR ligands, which may contribute to carcinogenesis in the stomach, colon and liver. Modulating the gut microbiome and/or bacterial translocation by probiotics or antibiotics may represent clinically feasible approaches to reduce TLR-mediated inflammatory and tumor-promoting signals. 178 In murine models of colon cancer, administration of synbiotics but not pro-or prebiotics alone, prevented aberrant crypt foci formation in AOM-induced colon cancer. 179, 180 In a rat model of liver carcinogenesis, administration of the probiotic VSL#3 strongly reduced liver tumor formation. 106 In a genetic mouse model of colorectal cancer, short-term antibiotic treatment reduces the pro-tumorigenic expression of IL-23 in tumor-associated macrophages while long-term depletion of gut microflora, reduces tumor number and size. 181 A recent study confirmed these findings in a different model of colon cancer, where gut sterilization limits the development of colonic dysplasia. 182 In liver cancer, gut sterilization by oral antibiotics results in drastically reduced tumor burden in mouse and rat models. 9, 51 Notably, effects of antibiotics are more pronounced when given at late stages of hepatocarcinogenesis, suggesting that gut microbiome modulation by antibiotics might be useful in clinical settings, where early prevention treatment typically is not possible. Although the above used antibiotics cannot be applied in patients long term, recent data also suggest that well-tolerated non-absorbable antibiotics such as Rifaximin reduce liver tumors in murine hepatocarcinogenesis. 9 Rifaximin is approved for the treatment of hepatic encephalopathy and is well-tolerated. 183 However, neither probiotics nor antibiotics have yet been studied for primary or secondary tumor prevention in patients. In advanced liver disease, Rifaximin could be used to hit 'two birds with one stone' by reducing hepatic encephalopathy and preventing liver cancer development.
TLR2 and TLR4 antagonist for tumor prevention. The TLR4 inhibitors CRX-526 and E5564 are synthetic analogs of the lipid A portion of LPS, and prevent binding of LPS to the TLR4-MD2 complex and TLR4 activation. TAK-242 is a TLR4 antagonist that acts on the intracellular domain of TLR4. Although these TLR antagonists effectively prevent LPS-mediated inflammation and lethality, [184] [185] [186] they have not been investigated in animal models or clinical trials for tumor prevention. Similarly, the TLR2 inhibitory humanized monoclonal antibody OPN305, reduces inflammation in vivo 187 but has not been investigated for tumor prevention.
CONCLUSION
Knowledge about the contribution of TLRs to cancer as well as clinical trials using TLR agonists for antitumor therapy have increased tremendously. One of the most relevant scientific discoveries in the field of TLRs and cancer biology in the past decade has been the realization that TLRs may promote tumor formation in certain organs such as the colon, stomach, pancreas and liver. This knowledge needs to be integrated into current future clinical trials. Although only few approaches have been found to be successful, including the local TLR7 agonist imiquimod and the nonspecific TLR2/TLR4 agonist BCG, testing of new TLR agonists, combinations and indications for TLR-based antitumor therapy is still ongoing. Integration of TLR agonists as adjuvants into DC-based cancer vaccination has become a new focus 77 that may constitute a new and efficient modality of tumor therapy in the future. Moreover, the tumor-promoting actions of some TLRs may open up new possibilities for primary or secondary tumor prevention. The fact that TLRs may also promote chronic inflammation and cancer in some settings should not deter from successes with TLR agonists as antitumor therapy, and requires further mechanistic investigations shedding light on the 'Yin and Yang' of TLRs in tumor biology.
